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Animal research suggests that the consolidation of fear and
extinction memories depends on N-methyl D-aspartate (NMDA)-
type glutamate receptors. Using a fear conditioning and extinction
paradigm in healthy normal volunteers, we show that postlearning
administration of the NMDA partial agonist D-cycloserine (DCS)
facilitates fear memory consolidation, evidenced behaviorally by
enhanced skin conductance responses, relative to placebo, for
presentations of a conditioned stimulus (CS) at a memory test
performed 72 h later. DCS also enhanced CS-evoked neural
responses in a posterior hippocampus/collateral sulcus region and
in the medial prefrontal cortex at test. Our data suggest a role for
NMDA receptors in regulating fear memory consolidation in humans.
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Introduction
Transforming a recently acquired memory into a durable
memory trace is a critical component of adaptive behavior.
Memory consolidation is also of considerable clinical interest in
the treatment of both memory dysfunction and anxiety
disorders such as posttraumatic stress disorder that may be
based on maladaptive learning processes. Successful consolida-
tion of many types of memories is believed to depend on early
activation of NMDA-type glutamate receptors, setting into
motion a cascade of molecular events that ﬁnally leads to
durable changes in synaptic properties (Martin 2000; Izquierdo
et al. 2006). The role of NMDA receptors in consolidation of
both emotional and nonemotional memories has been exten-
sively studied in rodents. In particular, there is evidence from
various animal models of fear conditioning that NMDA receptor
activation promotes fear memory consolidation (Stewart and
McKay 2000; Rodrigues et al. 2001; Rubin et al. 2004). By
contrast, there is a paucity of human data that address this
issue. One study has found evidence suggesting that NMDA
blockade impairs short-term consolidation of episodic memory
(Parwani et al. 2005), whereas another study has failed to ﬁnd
evidence for a presumed positive modulatory role of the NMDA
partial agonist D-cycloserine (DCS) on ‘‘extinction memory’’
consolidation (Guastella et al. 2007).
We investigated the contribution of NMDA receptors to
consolidation of conditioned fear and extinction memory. In
cued fear conditioning, an organism learns that an initially neutral
stimulus (conditioned stimulus [CS]) predicts a noxious stimu-
lus (unconditioned stimulus [UCS]), resulting in the formation
of a conditioned response (CR) to presentation of the CS and
a corresponding fear memory (CS--UCS association) (Pavlov
1927). To assess NMDA effects in fear memory consolidation,
we ﬁrst fear conditioned subjects and, postconditioning, admin-
istered either placebo or DCS (day 1). At a recall test 72 h later
(day 2), we compared both groups for CS-evoked CRs. In addition
to behavioral CR indices, we employed functional magnetic
resonance imaging (fMRI) to measure correlated neural activity
in predeﬁned regions of interest (ROIs).
Fear memories can be extinguished by repeated unreinforced
CS presentations, a process believed to involve formation of
a new, inhibitory memory (CS--noUCS association) (Myers and
Davis 2002; Bouton 2004; Delamater 2004). Successful recall of
this extinction memory (i.e., CR inhibition) depends critically on
the test context resembling the context in which extinction
originally took place (Bouton 2004). To assess NMDA effects in
extinction memory consolidation, we included extinction
training and an extinction test in a context different from the
context in which subjects were conditioned (see Fig. 1 for an
overview of the design and methodology). Due to the
contextualization of cued fear and extinction learning on day 1
in this paradigm, we expected context-dependent recall on day
2. That is, the fear memory should be preferentially recalled (an
CR should be produced) when the CS was presented in the
conditioning context, whereas the extinction memory should
be preferentially recalled (a signiﬁcantly smaller CR should be
produced)whentheCSwaspresentedintheextinctioncontext.
Based on the idea that consolidation involves NMDA activa-
tion, we predicted that DCS would enhance CRs in the
conditioning context, relative to placebo. A secondary pre-
diction was that such enhancement would be associated with
increasedCS-evokedactivationinareasimplicatedacrossanimal
and human studies in recall of contextualized fear memories,
namely posterior hippocampus and medial prefrontal cortex/
anterior cingulate cortex (MPFC/ACC; Kim and Fanselow 1992;
Maren and Fanselow 1997; Corcoran and Maren 2004; Frankland
et al. 2004; Corcoran et al. 2005; Ji and Maren 2005; LaBar and
Phelps 2005; Kalisch et al. 2006a). For CS presentations in the
extinction context, we predicted further reduced CRs and
concomitant neural activations in the DCS group.
Materials and Methods
The design consisted of Pavlovian fear conditioning in context A and
extinction in context B on day 1. This was followed by testing CS-
evoked responses in both the conditioning (A) and the extinction
context (B) on a subsequent day (day 2, see Fig. 1 for an overview). To
investigate the role of NMDA receptors in the consolidation of fear and
extinction memory, subjects received either DCS or placebo after the
experiment on day 1 in a randomized, double-blind, between-subject
fashion. Drug effects on consolidation were then assessed by
comparing the recall of fear and extinction memories on day 2
between the DCS and the placebo groups. In order to assure that the
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10--12 h), day 2 corresponded to 72 h after day 1.
Subjects
Thirty-two right-handed female volunteers, nonpregnant and non-
breastfeeding, participated in the study. In a face-to-face interview,
subjects were preassessed by an experienced psychiatrist to exclude
those currently under any medication or treatment, those with past or
present mental or neurological illness, kidney impairment, heart
condition, porphyria, porphyria among family members, and allergy to
antibiotics. All subjects gave informed written consent, and the study
was approved by the Joint Ethics Committee of the National Hospital
for Neurology and Neurosurgery. One subject withdrew from the study
3 days after ingestion of DCS, complaining about headaches. The
remaining 31 subjects had a mean age of 25 years (±1 year standard
error of the mean). Subjects were randomly assigned to 1 of the 2
treatment groups, 1 receiving placebo (n = 16, mean age = 26 ± 2 years)
and 1 receiving DCS (n = 15, mean age = 24 ± 1 years). Groups did not
differ in terms of trait anxiety as assessed by their average scores on
a trait anxiety inventory (STAI-T; Spielberger [1983]; 33.9 ± 2.4
(placebo) and 31.2 ± 1.7 [DCS], P = 0.252, 2-sample t-test, 2 tailed).
Stimuli
Unconditioned Stimulus
The UCS consisted of brief electric shocks to the right hand. Shocks
were applied using a Digitimer DS7A electrical stimulator (Digitimer
Ltd, Welwyn Garden City, UK) delivering electrical pulses of up to
20 mA and 1 or 2 ms duration through a silver chloride electrode.
Stimulation parameters were individually adjusted prior to the
experiment to achieve maximum tolerable pain. To this end, subjects
were given a series of shocks, starting at a very low current level and
slowly increasing in amplitude, until the subject indicated he or she did
not want to receive any higher stimulation. The subject was explicitly
asked whether the reached level was tolerable and could be used
during the subsequent experiment. Note that fear-related areas show
lateralized CS responses based on where the source of danger is located
in space (Blair et al. 2005; Kalisch et al. 2005). To increase the
probability of ﬁnding CS-evoked activation, we therefore applied the
UCS to the same hand (right) in all subjects. This prohibits inference
about lateralization of CS-evoked responses.
Conditioned Stimuli
The 2 CSs (1 CS+ that was occasionally paired with the UCS and 1 CS–
that was never paired) consisted of 1 male and 1 female face from the
Ekman series (Ekman and Friesen 1976) whose hair was removed in
view of the gender decision task (see below). Mildly (20%) angry faces
were chosen based on earlier studies by our group showing successful
conditioning and amygdala activation with mildly angry face CSs
(Morris et al. 1998; Critchley et al. 2002). The 2 same faces were used
for all subjects. In 15 of the 31 subjects (8 in the placebo and 7 in the
DCS group), the CS+ was the male face; in the remaining 16 subjects
(8 in the placebo and 8 in the DCS group), it was the female face.
Contexts
Conditioning and extinction occurred in 2 different contexts that were
distinguished by background screen color and auditory input. The
screen color was either black or rhythmically changing between red
and orange. The ﬁxation mark was a white cross in the black and
a white dot in the red--orange context. There was no auditory input in
the black context, whereas, in the red--orange context, subjects heard 2
sounds of different pitch, presented over headphones, which changed
synchronously with the color of the screen. In 16 subjects (8 in the
placebo and 8 in the DCS group), the black context was the context in
which conditioning occurred (conditioning context or A) and the red--
orange context was the context in which extinction occurred
(extinction context or B). In the remaining 15 subjects (8 in the
placebo and 7 in the DCS group), the red--orange context was the
conditioning context and the black context was the extinction context.
Task
Subjects were told that the study would examine attentional
performance under stress and its pharmacological manipulation and
were only debriefed at the end of the study. The task was a speeded
gender decision task for which subjects signaled the gender of the face
by pressing the left (for female) or the right (for male) button on
a keypad with their right hand’s index or middle ﬁnger, respectively, as
soon as they saw the face.
Drugs
DCS (King Pharamaceuticals, Leicester, UK; dose = 500 mg) was
administered as 2 tablets of 250 mg. This dose has apparent
(extinction) memory-enhancing effects in phobic patients treated with
exposure therapy (Ressler et al. 2004). Subjects were asked not to eat
3 h before start of the experiment. Fasting facilitates DCS absorption
(Zhu et al. 2001), and plasma concentrations peak within 2 h in sober
subjects (van Berckel et al. 1998). This measure was intended to assure
high DCS plasma levels during the theoretical critical time window for
NMDA-dependent memory consolidation of 1- to 2-h postlearning, as
determined in rats (Scavio et al. 1992). In addition, subjects were asked
to refrain from alcohol or other drugs on the eve of, and during, the
experimental days to limit potential drug effects on task performance
as well as potential DCS--drug interactions—which can have amnestic
effects in the case of ethanol (Trevisan et al. 2008). There were no
restrictions with regard to nicotine consumption. Two 100-mg vitamin
E tablets (Co-farmer, Hurts, UK) served as placebo.
Figure 1. Fear and extinction recall paradigm. On day 1, subjects (n 5 31 healthy
female volunteers) were fear conditioned to a CSþ (a face) through multiple pairings
with an UCS (electric shock) in context A (conditioning context, block A1). Fear
responses were then extinguished in context B (extinction context, block B1) through
multiple CSþ presentations in the absence of the UCS. To ascertain retention of fear
memories until a recall test 72 h later (see below), conditioning was repeated in
a further block (A2). As a control for nonassociative effects, we also employed
a nonpredictive CS  (a face of opposite gender) that was never paired with the UCS
and presented intermixed with the CSþ. Contexts were deﬁned by screen color and
auditory input. It was assumed that this procedure would create a CS-associated fear
memory. Based on an earlier study by our group (Kalisch et al. 2006a), it was also
assumed that the procedure would create an (extinction) context-dependent
extinction memory. Learning was followed by administration of either placebo (n 5
16) or 500-mg DCS (n 5 15). On day 2 (72 h later), CSs were presented in both
contexts A and B to test for CS-evoked fear and extinction memory recall,
respectively. To this purpose, each context was presented 16 times in alternating
order. Recall of fear memory in context A on day 2 was facilitated by additionally
presenting 1 unpaired shock at the beginning of each context A block, thus again
ﬁrmly associating context A with the UCS. The task was a speeded gender decision
task in response to the face stimuli. Gender of faces and conditioning and extinction
contexts were counterbalanced between groups. The design was randomized, double
blind, and between subject. Flash denotes electric shock.
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Day 1: Discrimination Learning and Drug Administration
Subjects were ﬁrst habituated to the CSs and contexts by presenting
each CS 3 times in each context prior to the actual experiment.
Subjects then learned to discriminate the 2 CSs on the basis of how
they predicted danger. In conditioning block A1, the CS+ and the CS–
were each presented 15 times in a randomized order in the center of
the screen. The duration of CSs ranged from 2 to 8 s with a mean
duration of 5.7 s per CS type (2 CSs of 2 s, 1 of 3 s, 3 of 5, 6, 7, and 8 s
each per CS type). The UCS was applied 250 ms before the offset of the
CS+. Those 3 CS+ presentations that were shorter than 5 s were not
coupled with an UCS, resulting in a reinforcement ratio of 80%. Varying
delays between CS+ and UCS onset were meant to introduce additional
uncertainty that would make conditioning somewhat more extinction
resistant and therefore increase the likelihood of recall of fear memory
on day 2, an effect that, according to our experience (Kalisch et al.
2006a), is difﬁcult to obtain in humans and that we expected to be even
more difﬁcult to reproduce with a relatively long acquisition-test
interval of 72 h. For the same reasons, the number of conditioning trials
was increased compared with our earlier study where the acquisition-
test interval was 24 h only (Kalisch et al. 2006a). A minimum delay of
5 s between CS+ and UCS onset allowed us to measure conditioned skin
conductance responses (SCRs) to the CS+ without a confound from the
subsequent unconditioned SCRs to the shock. CSs were separated by an
interstimulus interval (ISI) of 9 s during which subjects saw a central
ﬁxation mark (low-level baseline). The length of the ISI was chosen to
avoid complete masking of conditioned SCRs by preceding uncondi-
tioned SCRs to the shock.
In the following extinction block B1, which was different from the
preceding conditioning block in terms of screen color and auditory
input (see above), conditioned fear responses were extinguished by
presenting the same 30 CSs in the same fashion but without shock. This
was followed by another conditioning block (A2) in its corresponding
context. This design allowed subjects to learn to discriminate between
2 different contexts on the basis of whether the CS+ was (conditioning
context) or was not (extinction context) associated with the UCS. Each
block lasted 6 min, and the corresponding context was already present
at the beginning of each block 9 s before CS presentation started.
Blocks were separated by a break of 30 s during which scanning
continued, but subjects were allowed to close their eyes if they wanted.
Immediately (within 2 min) after the end of the experiment, subjects
received either placebo or DCS. Following this, the subjects were asked
whether they had noticed any relationship between the shock and the
gender of the face and between the shock and the screen color.
Twenty minutes after drug intake, subjects ﬁlled in a 7-item physical
symptoms rating for dry mouth, dry skin, blurred vision, sedation,
nausea, dizziness, and headache (rated not present, very mild, mild,
moderate, moderately severe, severe, or extremely severe) and a 17-
item mood rating scale using visual analog scales for pairs of words
(alert--drowsy, tense--relaxed, etc.) as suggested by Bond and Lader
(1974). Thirty minutes after drug intake, the subjects were allowed to
leave the department.
Day 2: Memory Test 72 h Later
Subjects again completed the physical symptoms and mood rating
scales. Then, each context was again presented 18 times in an
alternating order (ABABAB...) for a duration of 29 s each, separated
by 5-s breaks. At the beginning of each block, the context was present
without any CS for 10 s. In 16 out of the 18 blocks of A and B each, 1
CS+ and 1 CS– were presented in random order for a duration of 5 s
each, followed by an ISI of 4 s each. In those 16 A blocks, subjects
received a shock 3 s after the beginning of the block that was, however,
not paired with either the CS+ or the CS–. Associating context A with
shock during recall theoretically promotes reinstatement, thus facili-
tating recall of the CS-associated fear memory in this context. This was
another measure taken to increase the likelihood of fear memory
recall on day 2 that should be additionally compromised by the ongo-
ing extinction of CRs as a consequence of repeated unreinforced
CS+ presentation at test (for detailed discussion, see Kalisch et al.
[2006a]).
Efﬁciency of Blinding and Drug Side Effects
Before debrieﬁng, subjects were asked whether they thought they had
received drug or placebo. Out of 31 subjects 20 answered they did not
know. Four placebo subjects correctly guessed that they had received
placebo, whereas 2 placebo subjects incorrectly guessed that they had
received drug. Four drug subjects correctly guessed that they
had received drug, whereas 1 drug subject incorrectly guessed that
she had received placebo. Correct guesses were most likely due to the
absence/presence of side effects. In the mood rating scale completed
20 min after placebo/drug intake, drug subjects reported to feel more
mentally slowed (compared with quick witted, mean = 5.3 ± 0.6) than
placebo subjects (mean = 7.2 ± 0.4, P = 0.012, unpaired t-test, 2 tailed).
Otherwise, the mood rating scale as well as the physical symptoms
rating scale did not pick up any signiﬁcant group differences, whether
employed on the day of drug intake or at the beginning of the
experiment on day 2. However, on day 2, 6 drug subjects but only 1
placebo subject told the experimenters of headaches typically starting
a few hours after intake on day 1 and lasting a few hours up to a day.
Additional side effects thus reported but not picked up by the rating
scales were tiredness/lethargy (3 drug subjects), dizziness (3 drug
subjects), nausea (2 drug subjects), and feeling hot/sweaty (1 drug
subject). This suggests that a limited number of subjects may have been
effectively unblinded. It is unlikely, though, that this inﬂuenced our
measures of recall, given that these were incidental and subjects were
not aware of the true purpose of the task.
Autonomic Monitoring
Skin conductance measurements were acquired at a sampling rate of
1000 Hz from electrodes on the middle and ring ﬁnger of the left hand
using an AT64 SCR apparatus (Autogenic Systems, Wood Dale, IL).
Imaging
Subjects were scanned on both days to maximize context identity
across days. Only data from day 2 are reported here. A 3 Tesla MR head
scanner (Magnetom Allegra, Siemens, Erlangen, Germany) was used to
acquire gradient echo T  
2 -weighted echo-planar images (EPI) with
blood oxygen level--dependent contrast (time echo = 30 ms, time
repetition = 1.43 s, ﬂip angle = 70, slice tilt = 30, z-shim gradient
prepulse = –1 mT/m ms). Each volume comprised 22 oblique axial
slices of 2-mm thickness and 3 3 3m m
2 in-plane resolution with a slice
gap of 1 mm. The slice package excluded the dorsal frontal, parietal,
and occipital cortices. These parameters produced EPIs in which signal
dropout due to susceptibility-induced ﬁeld inhomogeneities was
minimized for amygdala and orbitofrontal cortex (Deichmann et al.
2003). Subjects were placed in a light head restraint within the scanner
to limit head movement during acquisition. A total of 1064 (day 1) and
899 (day 2) volumes were acquired continuously throughout the task,
at 1.43-s intervals, starting 14.3 s before the onset of the experiment. As
a result of the above timings, there was no systematic temporal
relationship between the onsets of slices and stimuli, thus allowing for
sampling, over the course of the experiment, the entire length of the
stimulus-driven hemodynamic responses in each of the 22 slices. A T1-
weighted structural image was also acquired (Deichmann et al. 2004).
Data Analysis
Behavioral Data
Skin conductance data were downsampled to 100 Hz, mean ﬁltered,
and then visually inspected for artifacts. Eight subjects did not show any
apparent SCR to the UCS on day 1 and were excluded from further skin
conductance analysis, reducing sample size (including for the imaging
data analysis where SCR scores were used to model CR magnitude, see
below) to n = 23 (n = 13 in the placebo and n = 10 in the DCS group).
In the following, an SCR was deﬁned as the maximum skin conductance
in a time window of 5 s after CS onset minus skin conductance at the
time of CS onset (Buchel et al. 1998). Data were z-transformed to
account for interindividual differences in physiological reactivity
(Buchel et al. 1998). In 2 subjects on day 1, reaction time (RT)
recording failed for technical reasons, reducing sample size on day 1 to
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data from the gender decision task were z-transformed.
Signiﬁcance of behavioral effects was assessed using t-tests and
analysis of variance (ANOVA). Because we had directed hypotheses for
both SCR and RT effects, a 1-tailed threshold of P = 0.05 was used
throughout, unless indicated otherwise. On day 1, where early and late
experimental blocks were analyzed separately (LaBar et al. 1998; Phelps
et al. 2004), this was done by subtracting responses to the ﬁrst 8 CS–
from the ﬁrst 8 CS+ (early) and responses to the last 7 CS– from the
last 7 CS+. Note that the order of CS+ and CS– was randomized. This
means that some of the CSs classiﬁed as early may effectively have
occurred in the last half of the block and some of the late CSs in the ﬁrst
half. However, such potential minor distortions should randomize out
at the group level.
Response accuracy was 100% in all subjects (n = 29) recorded in all 4
conditions (CS+ in A, CS– in A, CS+ in B, and CS– in B) on day 1. On day
2, response accuracy ranged between 87.5% and 100% across subjects
and conditions. The CS+ versus CS– difference scores were not
signiﬁcantly inﬂuenced by either context (A vs. B) or treatment (DCS
vs. placebo) as assessed by 2-way repeated measures ANOVA.
Imaging Data
Imaging data were analyzed using SPM2 (www.ﬁl.ion.ucl.ac.uk/spm;
Ashburner et al. 2004). The 10 initial images were discarded to account
for T1 equilibration. Scanner hardware problems caused occasional
high--signal intensity artifacts (spikes) in 5 subjects. The affected slices
were discarded and replaced by the mean of the preceding and the
subsequent slice. To correct for motion artifacts, images were realigned
to the 11th volume. Images were unwarped to correct for movement-
by-distortion interactions, spatially normalized to a standard EPI
template, spatially smoothed using a Gaussian kernel with a full width
at half maximum (FWHM) of 4 mm, temporally high-pass ﬁltered
(cutoff = 128 s) and corrected for temporal autocorrelations using ﬁrst-
order autoregressive modeling. Statistical analysis was performed using
a standard approach for fMRI, involving a general linear convolution
model at the single-subject level and a random effects analysis at the
group level (see Friston et al. 1994; Friston et al. 1995; Penny and
Holmes 2004 for details). First, for each subject, condition-speciﬁc
regressors were deﬁned that modeled the time course of the
experimental events and, after convolution with a canonical hemody-
namic response function, served as predictors of the fMRI signal time
courses at each voxel in the brain. CSs were modeled as a series of
events (i.e., a series of delta functions, separately for CS+ in A, CS– in A,
CS+ in B, and CS– in B). Additionally, these 4 categorical regressors were
parametrically modulated using trial-by-trial z-transformed SCRs as an
index of the magnitude of the evoked CR. Shocks were also modeled as
events, whereas A and B blocks were modeled as 2 separate boxcar
regressors (0 for off and 1 for on). As mentioned above, each regressor
was convolved with a canonical hemodynamic response function. Using
these regressors in a general linear model (multiple regression) of brain
activation at each voxel yields parameter estimates of the contribution
of each regressor to the fMRI signal measured in each voxel. Contrasts,
that is, linear combinations of these parameter estimates, were then
calculated voxel-wise to produce within-subject estimates of effects of
interests (e.g., the contrast CS+ minus CS– in context A). Statistical
inference was obtained using a t-statistics that takes into account the
magnitude of the contrast value and its standard deviation. This yielded
single-subject statistical parametric maps (SPM T maps) for each
contrast of interest. For the random effects group analyses, the subject-
speciﬁc contrast images were spatially smoothed (FWHM = 10 mm) to
account for intersubject variation in the exact location of activations
and compared across subjects. Within-group effects (i.e., effects within
either the placebo or the DCS group) were tested for signiﬁcance using
voxel-wise 1-sample 1-tailed t-tests. Between-group effects (treatment
effects) were tested using 2-sample unpaired t-tests. Averaged single-
subject contrast estimates were used to illustrate group effect sizes in
selected voxels (insets in the ﬁgures).
Correction for multiple comparisons following Gaussian random ﬁeld
theory was limited to predeﬁned spherical ROIs (small volume
correction [SVC]) and included all voxels active at an uncorrected
threshold of P = 0.01. The bilateral amygdala (coordinates ±28, –2, –32)
and posterior hippocampus (±38, –32, –12) ROIs for recall of fear
memory were taken from Kalisch et al. (2006a) from their contrast
(CS+ > CS–)A, RT-modulated (see their ﬁg. 3). The bilateral MPFC/ACC
ROI for anticipatory fear (coordinates ±2, 45, 27) was taken from
Kalisch et al. (2005). The same coordinates have since successfully
been used in 2 further studies (Kalisch et al. 2006b, 2006c) to identify
MPFC/ACC activation during anticipatory fear. All ROIs had a radius of
6 mm around the seed point. Bilateral ROIs were chosen because the
cited reference studies, albeit partly reporting unilateral coordinates
only, did not test and were not designed to test lateralization (due to
UCS application to the same hand in all subjects, as in the present
study).
Structural images were coregistered onto functional images and
spatially normalized using the nonlinear transformation estimated from
the functional EPIs. Anatomical localization was carried out with
reference to the atlas of Duvernoy (1999). Coordinates are described in
the standard space deﬁned by the Montreal Neurological Institute.
Results
Day 1: Fear Conditioning and Extinction
Out of 31 subjects 23 (11 in the placebo group and 12 in the
DCS group) reported awareness of the CS+--UCS contingency
and 28 out of 31 subjects (15 in the placebo group and 13 in
the DCS group) reported awareness of the context A--UCS
contingency when interviewed after the experiment on day 1,
suggesting successful conditioning and context discrimination.
Conditioning was conﬁrmed by analysis of CS-evoked SCRs.
Figure 2a shows larger SCRs to the CS+ than to the CS– in the
ﬁrst conditioning block (A1). The effect reached signiﬁcance in
the second half of the ﬁrst conditioning block (A1 late: t(22) =
2.19, P = 0.02, paired t-test, 1 tailed), that is, after an initial
learning phase (A1 early). (For a separate depiction of SCRs
evoked by CS+ and CS–, see Supplementary Fig. 1.) This
differential SCR effect extended into the ﬁrst half of the
subsequent extinction block (B1 early: t(22) = 1.82, P = 0.041).
Figure 2. SCRs showing facilitated fear memory consolidation by DCS. (a) Day 1:
Signiﬁcantly larger SCRs to the CSþ than to the CS  during late fear conditioning in
context A indicate learning of the CSþ UCS contingency (fear memory) in context A
on day 1. A reversal of the conditioning effect during late extinction in context B
indicates learning of the CSþ noUCS contingency (extinction memory) in context B.
(b) Day 2: SCRs to the CSþ in the conditioning context were again signiﬁcantly larger
than to the CS  on day 2, but only in those subjects receiving DCS after learning on
day 1. A similar effect was apparent in the extinction context, that is, there was no
evidence for extinction memory recall. Scale: z scores (unit: standard deviations
[SDs]). *P \ 0.05, (*)P \ 0.1, 1-tailed t-test versus 0.
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(A2) (but compare the change relative to the preceding (late)
extinction block).
The SCR data also showed evidence of successful extinction
in context B. During the second half of the extinction block
(B1 late), SCRs to the CS+ tended to become smaller than to the
CS– (t(22) = –1.67, P = 0.054). That is, extinction learning not
only abolished but also reversed the conditioning effect. The
context discrimination effect ((CS+ > CS–)A > (CS+ > CS–)B)
was signiﬁcant when comparing A1 late to B1 late (t(22) = 2.4,
P = 0.013). There were no signiﬁcant differences between
those subjects who were subsequently treated with placebo
versus those treated with DCS (ingested immediately following
learning). We observed no signiﬁcant RT effects in the gender
decision task.
Day 2: Recall of Fear Memory as a Function of
Postlearning Drug Treatment
Placebo
In the placebo group, test at 72 h showed no differential (CS+ >
CS–) SCRs in either context nor was there any contextual
modulation of SCR differences (Fig. 2b). The data indicate an
absence of fear memory recall 72 h after learning. Given the
apparent decay of fear memory, no conclusions about
extinction memory recall (which can only be deduced from
a reduction of CRs) can be drawn. Absence of CRs in the
placebo group highlights the difﬁculty to obtain fear memory
recall in human subjects (where the UCS does not evoke
substantial threat and the conditioning experience can be
cognitively reappraised) despite a relatively extended condi-
tioning procedure on day 1 and presentation of unpaired UCSs,
which theoretically promotes reinstatement of fear, in the
conditioning context on day 2 (see Materials and Methods).
D-Cycloserine
By contrast, the DCS group showed signiﬁcant differential SCRs
in both contexts, indicating recall of fear memory independent
of context (A: t(9) = 1.91, P = 0.044; B: t(9) = 2.33, P = 0.022;
Fig. 2b). SCR differences reached levels similar to block A1 late
on day 1 (compare Fig. 2a). This effect did not differ between
contexts ((CS+ > CS–)A > (CS+ > CS–)B: t(9) = 0.17, P = 0.435);
that is, there was no evidence for recall of extinction memory
(comparatively reduced CRs) in the extinction context. As on
day 1, there were no RT effects in either group (see
Supplementary Fig. 2).
Placebo versus DCS
The group comparison showed that postlearning drug treat-
ment had a signiﬁcant inﬂuence on our SCR measure of fear
memory recall. A 2-way repeated measures ANOVA with
treatment (placebo, DCS) as between-subject factor, context
(A, B) as within-subject factor, and the SCR CS+ > CS–
difference score as the independent variable revealed a signif-
icant effect of treatment (F1,21 = 5.7, P = 0.026) but no effect of
context (F1,21 = 0.03, P = 0.86) and no treatment by context
interaction (F1,21 = 0.0, P = 0.948). Planned post hoc t-tests
showed that in the conditioning context A, where we
predicted stronger recall of fear following DCS treatment, the
DCS subjects had increased differential SCRs compared with
the placebo subjects (t(21) = 1.99, P = 0.03, unpaired t-test, 1
tailed). This suggests that DCS treatment facilitated fear
memory recall at test. The DCS subjects also had larger
differential SCRs in the extinction context B, but the effect did
not reach signiﬁcance (t(21) = 1.57, P = 0.131, 2 tailed). The
data thus allow no inferences on the role of DCS in extinction
memory consolidation within the context of our experimental
design.
Day 2: Neural Activity Associated with Fear Recall
Facilitation by DCS
Our behavioral data showed a treatment effect on differential
responses to CS+ versus CS– stimuli 72 h after treatment. To
capture this effect in our analysis of the fMRI data from day 2,
we modeled CS-evoked responses as events. Moreover,
categorical effects were parametrically modulated by trial-by-
trial SCRs as an index of CR magnitude (Carter et al. 2006). That
is, the statistical model included 1 categorical regressor per
trial type (CS+A,C S –A,C S +B,C S –B) that predicted equivalent
hemodynamic activation for each trial of a trial type. In
addition, there was 1 parametric regressor per trial type that
predicted activation varying with SCRs over trials and hence
expressed the behaviorally determined magnitude of the
associated CR (see Materials and Methods). The behavioral
results led us to focus our analysis on differential (DCS >
placebo) parametric activations in areas related to fear recall.
Bilateral hippocampal ROIs were deﬁned based on an earlier
study by our group (Kalisch et al. 2006a) where fear recall was
tested 24 h after conditioning, yielding CS+-evoked activation
in posterior hippocampus. Because the same study had also
produced amygdala activation, albeit at lower threshold, and
because of the documented role of the amygdala in cued fear
recall in rats (Schafe et al. 2005), we also included bilateral
amygdala ROIs (see Materials and Methods for coordinates).
Bilateral MPFC/ACC ROIs were deﬁned based on studies of
anticipatory fear for impending pain that used explicit in-
structional learning to fear condition subjects and tested for
CRs at variable delays after conditioning (see Materials and
Methods).
As indicated above, the behavioral results suggested that the
data could be collapsed across contexts, thereby maximizing
statistical power in the fMRI analysis. To ensure that this was
justiﬁed, we ﬁrst tested the placebo and the DCS data
separately for differences in the contrast (CS+ > CS–)a s
a function of context ((CS+ > CS–)A vs. (CS+ > CS–)B). As
expected, there were only minor differences (some voxels
active at a threshold of P < 0.001 uncorrected for multiple
comparisons) between contexts in either group, irrespective of
whether the categorical or the parametric effects were
examined; no differences were observed in the ROIs (data
not shown). The following analysis therefore reports collapsed
data only.
We observed a signiﬁcant parametric interaction of the type
treatment (DCS > placebo) by stimulus (CS+ > CS–) in the left
hippocampal and right MPFC/ACC ROIs. Both activations
survived correction for multiple comparisons within the
respective search volume (SVC; see Materials and Methods) at
a threshold of P < 0.05 (left posterior hippocampus:
coordinates x = –34, y = –32, z = –16, P = 0.022 SVC; bilateral
MPFC/ACC: x = 2, y = 46, z = 34, P = 0.009 SVC, x = –2, y = 46,
z = 34, P = 0.011 SVC, x = –2, y = 48, z = 28, P = 0.012 SVC;
unpaired 2-sample t-test, 1 tailed; see Supplementary Table 1
for details). For the activation peak in the hippocampal ROI,
our anatomical precision was not sufﬁcient to segregate
Cerebral Cortex January 2009, V 19 N 1 191between a localization in hippocampus versus collateral sulcus;
the MPFC/ACC peak was consistent with Brodmann area 9
(Fig. 3). By analogy to our earlier study (Kalisch et al. 2006a),
a corresponding amygdala activation was only observed at
trend-level signiﬁcance (left amygdala: x = –30, y = 2, z = –36, P =
0.082 SVC; right amygdala: x = 32, y = –4, z = –28, P = 0.086
SVC). Inspection of averaged single-subject contrast estimates
in hippocampus/collateral sulcus and MPFC/ACC (Fig. 3)
conﬁrmed differential (CS+ > CS–) activation of both areas in
the DCS, but not placebo, group across contexts. This suggests
that enhanced fear memory consolidation with DCS adminis-
tration, as indexed in behavior, was also expressed in enhanced
neural activity at recall within the posterior hippocampus/
collateral sulcus and the MPFC/ACC. No signiﬁcant effects
were observed in the corresponding categorical contrast.
Supplementary Table 1 gives results from the entire scan
volume and from the within-group contrasts; Supplementary
Table 2 gives results from context A only.
Discussion
We provide behavioral and neuronal data indicating that DCS
administration following acquisition of cued conditioned fear
facilitates recall of the conditioned memory at test in humans.
DCS administration postlearning led to signiﬁcantly enhanced
SCRs to CS+ probes presented 72 h later, at a time where
placebo subjects showed no CS+-evoked SCRs. This was
accompanied by CS+-evoked activation, in the DCS group,
within the posterior hippocampus and/or collateral sulcus and
the MPFC/ACC. On this basis, we suggest that NMDA receptor
activation is involved in fear memory consolidation in humans.
A large animal literature has demonstrated the importance of
NMDA receptor activation in fear memory consolidation.
NMDA antagonists administered postlearning impair the later
recall of fear in cued (Rodrigues et al. 2001; Rubin et al. 2004)
and context fear conditioning (Stewart and McKay 2000;
Rodrigues et al. 2001; Rubin et al. 2004) and in avoidance
learning paradigms (reviewed in Izquierdo et al. [2006]). In
a minority of studies (Scavio et al. 1992; Gould et al. 2002),
NMDA antagonists showed a facilitatory effect. Our results
support the former ﬁndings, though we acknowledge that
a partial agonist like DCS can show antagonistic behavior when
endogenous ligand levels are very high. This might be the case
during severe stress, a potential corollary of the testing and
scanning procedures in this experiment. In particular, DCS is
only a weak partial agonist at NMDA receptors that bear the
NR2A and NR2B subunits (e.g., Sheinin et al. 2001) and that are
likely to be involved in conditioning- and extinction-related
synaptic plasticity (e.g., Rodrigues et al. 2001; Bauer et al. 2002;
Sotres-Bayon et al. 2007). In any case, our results strongly
suggest an involvement of NMDA receptors in fear memory
consolidation in humans.
The only human study indicating a role of NMDA receptors
in memory consolidation reported a deleterious effect of the
NMDA antagonist ketamine on episodic memory recall when
given immediately after learning (Parwani et al. 2005).
However, drug administration in this study was continued
throughout recall. The ﬁndings are also hard to reconcile with
other episodic memory studies where ketamine impaired recall
when given during learning but not when given immediately
after learning (Hetem et al. 2000; Honey et al. 2005). Such
inconsistent effects of NMDA receptor manipulations may best
be explained by the short interval of less than 60 min between
learning and recall in these experiments. Rat data show that
fear memory recall 24 h and 7 days, but not 3 h, after learning is
affected by NMDA agonists and antagonists (Lee et al. 2006), in
agreement with ﬁndings from other molecular pathways
generally showing that different systems support the consol-
idation of long- versus short-term memory (Izquierdo et al.
2006). The existing human data thus appear to mirror the time
frame of effects seen in animals.
In the present study, we were able to replicate ﬁndings from
Kalisch et al. (2006a) of hippocampal and (at lower threshold)
amygdalar activations during recall of fear memory. Because we
here tested for fear recall 72 h after conditioning (as opposed
to 24 h in Kalisch et al. [2006a]), we also expected medial
prefrontal/anterior cingulate activations. This hypothesis was
based on rodent studies of trace and context fear conditioning
that have shown a contribution of the MPFC/ACC to the recall
of remote fear memories (Takehara et al. 2003, Frankland et al.
Figure 3. Effects of postlearning DCS on fMRI correlates of recall of fear memory on day 2. Activations associated with recall of fear memory on day 2 in left posterior
hippocampus/collateral sulcus (x 5  34, y 5  32, z 5  16) (a) and right MPFC/ACC (x 5 2, y 5 46, z 5 34) (b) were larger in the DCS than in the placebo group. Images
show the parametric contrast (CSþ[CS )DCS[(CSþ[CS )placebo, display threshold P # 0.01. Hair cross denotes activation peak surviving SVC at P # 0.05. Activations
are superimposed on the mean structural image. The bar graphs show average contrast estimates for the parametric CSþ [ CS  contrasts in both groups and contexts.
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d Kalisch et al.2004; Runyan et al. 2004). The rodent literature did not allow
us to deﬁne a circumscribed medial prefrontal ROI. Using
a conservative analytical approach, we therefore took advan-
tage of a large human fMRI literature on anticipatory fear for
impending pain, a paradigm where subjects have to recall
a cue-pain contingency to prepare for the signaled application
of a painful stimulus. Consistent with a crucial role for the
MPFC/ACC in fear recall, an earlier review of the literature (see
Materials and Methods in Kalisch et al. [2005]) identiﬁed the
MPFC/ACC (mean coordinates –2, 45, 27) as the area most
consistently activated across anticipatory fear studies. Sub-
sequent experiments have successfully employed these coor-
dinates to identify anticipatory activation in the MPFC/ACC
(Kalisch et al. 2005, 2006b, 2006c). MPFC/ACC activation in
these studies appeared as large clusters spanning both
cingulate and medial prefrontal areas, with activation peaks in
Brodmann areas 9 and 32. Areas 9 and 32 are connected with
medial temporal and cingulate areas (Amaral and Price 1984;
Carmichael and Price 1995) and thus in a position to process
emotional information. We have been able to demonstrate
engagement of this region during emotional appraisal of
stimuli, a process that can involve recall of fearful associations
(Kalisch et al. 2006b). The functional signiﬁcance of MPFC/
ACC for fear recall is further substantiated by the fact that
MPFC/ACC responses in the present study scaled with the
magnitude of the CS+-evoked CR, as modeled using trial-by-trial
SCRs as a parametric modulator of the neural CS+-evoked
response. Thus, our ﬁnding of prior DCS treatment enhancing
conditioned responding of a functionally deﬁned subregion of
the medial frontal wall is in agreement with the previous
literature and points to a key role for this speciﬁc region in fear
recall in humans. Given the indirect derivation of our MPFC/
ACC ROI, we cannot exclude a contribution of other medial
prefrontal areas identiﬁed in the same contrast, notably the
bilateral ventral MPFC and the right rostral ACC (see
Supplementary Table 1). Activation patterns in the latter foci
were similar to the one shown for the MPFC/ACC in Figure 3b
(see Supplementary Fig. 3).
We note that DCS effects in the hippocampus and the
MPFC/ACC were driven in part by a smaller response to CS–
compared with CS+ in the placebo group. Comparison of CS+
and CS– responses between groups (i.e., CS+DCS vs. CS+placebo
and CS–DCS vs. CS–placebo) suggested that this effect was mainly
due to group differences in CS+ responses rather than in CS–
responses (data not shown). Speculatively, this might reﬂect
some degree of inhibition of CS+ responses in the placebo
group, perhaps related to online extinction in the absence of
negative reinforcement on day 2. Such CS+ < CS– differences
have also been observed by Phelps et al. (2004) during
extinction. If this interpretation is correct, one could conclude
that there must be at least some fear memory recall in the
placebo group on day 2, as otherwise there could be no
extinction.
Our design, involving postlearning drug administration and
a delayed recall test, minimizes potential confounds. First,
because the drug was given after learning, the observed
facilitation of recall on day 2 cannot be attributed to a potential
DCS effect on learning on day 1. And second, the fact that we
measured recall 72 h after drug administration makes it highly
unlikely that DCS affected recall itself. DCS has a plasma half-life
of approximately 10--12 h, that is, the recall test occurred after
6--7 half-lives. With an estimated peak plasma concentration
of 125 lM at 1.5 h after intake (compare van Berckel et al.
[1998]), plasma levels at test would have dropped to 2 lMo r
less. We do not know corresponding brain concentrations and
their dose--response relationships for DCS and thus cannot
absolutely exclude that residual DCS at test affected fear recall.
Yet, it is noteworthy that DCS present at test does not affect or
may decrease, rather than enhance, fear responses in human
and rat models of conditioned or unconditioned fear (Anthony
and Nevins 1993; Karcz-Kubicha et al. 1997; Klodzinska and
Chojnacka-Wojcik 2000; Heresco-Levy et al. 2002; Walker et al.
2002; Ressler et al. 2004; Mao et al. 2006; Yang et al. 2007). In
the light of a pronounced enhancing effect on fear recall in our
study, we suggest that the most likely explanation for our
results is a facilitatory effect of DCS on fear memory con-
solidation, but not on recall itself. A potential confound that our
design is not able to exclude is a possible inﬂuence of adverse
drug side effects, which were reported by a majority of subjects
in the DCS group (see Materials and Methods), on memory
consolidation. Adverse side effects may induce stress and
a concomitant rise in stress hormone levels, factors known to
inﬂuence emotional memory (McGaugh 2004). However,
a facilitatory role of endogenous cortisol on fear memory
consolidation is observed only in male subjects and in subjects
with high cortisol levels (Zorawski et al. 2006), suggesting
a rather minor impact of this factor in our (random female)
sample. Furthermore, subjects usually reported onset of side
effects several hours after the experiment, that is, after the
theoretical critical time window for NMDA-dependent memory
consolidation of 1--2 h postlearning, as determined in rats (Scavio
et al. 1992). A more plausible explanation for the observed
effects therefore is DCS action on the NMDA receptor.
In rats, DCS facilitates extinction learning (Walker et al.
2002). The effect is due to the enhancement of extinction
memory consolidation as the drug does not improve within-
session extinction learning but recall of the extinction memory
at a later test, an effect that is also observed when the drug is
given immediately after extinction training (Ledgerwood et al.
2003; for recent reviews, see Davis et al. [2006] and Vervliet
[2007]). DCS has been successfully employed to augment
extinction-based (i.e., exposure) therapy of height phobia
(Ressler et al. 2004), social phobia (Hofmann et al. 2006), and
obsessive-compulsive disorder (Kushner et al. 2007). However,
so far, there is no proof that, in humans, DCS acts by facilitating
extinction memory consolidation. One experimental condi-
tioning study failed to show any beneﬁcial effect of DCS on skin
conductance and shock expectancy measures of extinction
memory (Guastella et al. 2007), possibly due to a ﬂoor effect
related to very rapid and near-complete fear extinction already
in the placebo group. From our data, we are unable to draw any
conclusions about potential DCS effects on extinction memory
consolidation as there was no evidence of recall of extinction
memory on day 2 in the ﬁrst place. In the placebo group,
subjects showed no behavioral signs of recall of fear memory in
the conditioning context on day 2, a necessary comparison
condition against which to measure loss of fear (i.e., extinction)
in the extinction context. In the DCS group, although there
was apparent fear memory recall in the conditioning context,
very similar CRs were observed in the extinction context as
well. There are at least 2 potential reasons for this absence of
extinction effects on day 2 that are in contrast to our previous
study that showed reduced CRs in an extinction context at test
(Kalisch et al. 2006a). First, to avoid a potential ﬂoor effect, we
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blocks (A1, A2) on day 1, whereas in the previous study, the last
conditioning block (A2) had been followed by another
extinction block. Thus, despite evidence for extinction
learning on day 1, this may have been insufﬁcient to create
a (stable) extinction memory manifesting on day 2. Second, the
acquisition-test interval was 72 h in this study compared with
24 h in the previous study, a modiﬁcation we introduced to
guarantee a drug-free state at test. However, this may
effectively have contributed to a further decline of any
remaining extinction memory trace (and also of any remaining
fear memory trace in the placebo group). Other potential
reasons for an absence of extinction memory recall in the DCS
group are interactions of DCS with menstrual cycle or subjects’
potential alcohol consumption (Trevisan et al. 2008) that might
theoretically affect (impair) extinction memory consolidation
more strongly than fear memory consolidation. Finally, it
cannot be excluded that, particularly in humans, the NMDA
receptor subtypes involved in fear versus extinction memory
consolidation differ in terms of their subunit composition and,
hence, in their DCS response. DCS might thus preferentially
enhance fear memory consolidation in humans, although the
above clinical results would argue against this interpretation. As
a result of these shortcomings of the study, the question
whether and how DCS interacts with extinction learning in
humans awaits further experimental clariﬁcation.
Given a high intraindividual trial-by-trial variability in CR
magnitude, as is commonly observed in human fear condition-
ing studies, we modeled CS-evoked neural responses as
proportional to trial-by-trial CR magnitude, determined using
our skin conductance index of conditioning (see Materials and
Methods). This method should theoretically be more sensitive
in detecting CR-related brain activity than a simple categorical
analysis that ignores the possibility of ﬂuctuations in CR
magnitude over time. The method should therefore reduce
the likelihood of a type II error while not compromising on
type I error probability. Similar approaches, modeling an
exponential (Buchel et al. 1998) or stepwise (LaBar et al.
1998) decline in CR magnitude over the course of the
experiment on purely theoretical grounds, have allowed for
identifying the amygdala as a major component of the human
fear conditioning circuitry in the ﬁrst fMRI studies on fear
conditioning. More recently, researchers have tended to use
behavioral data-driven approaches (e.g., Seymour et al. 2004;
Carter et al. 2006; Kalisch et al. 2006a) as these generate
biologically more plausible predictions of activity time courses.
We have presented evidence suggesting involvement of
NMDA receptors in the consolidation of human fear memory.
Our ﬁndings will require corroboration from experiments with
an NMDA antagonist such as ketamine, in particular because
DCS, although safe, well tolerable, and therefore highly suitable
for human experiments, is only a partial agonist. Likewise,
future experiments should use a range of doses of DCS to
establish dose dependency. An important topic for future
research will be how the NMDA system interacts with other
neurotransmitter and hormone systems, such as the stress
hormone system, known to be crucial for memory consolida-
tion (McGaugh 2004). Our research opens the possibility of
using psychopharmacological manipulations in conjunction
with fMRI to provide insights into therapeutic strategies for
treating mental conditions associated with memory impairment
or pathologically enhanced memories.
Supplementary Material
Supplementary material can be found at http://www.cercor.
oxfordjournals.org/.
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